Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Diagnostic accuracy of biopsy urease tests for <i>Helicobacter pylori</i> infection in the gastric antrum and body.

The National medical journal of India·2018

Same author

<i>Helicobacter pylori</i>, acid secretion and serum gastrin.

The National medical journal of India·2018

Same author

Recurrent intestinal obstruction with acquired angio-oedema, due to C1-esterase inhibitor deficiency.

The Journal of the Association of Physicians of India·2015

Same author

Evaluation of Wound Healing Activity of Ethanolic Extract of Pongamia pinnata Bark.

Drug research·2015

Same author

Mononucleosis-like drug rash: an interesting case presentation.

Journal of family medicine and primary care·2014

Same author

Dr Ratanlal Harichand Kalro (1945-2013).

Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology·2014

Search research articles

Related Experiment Video

Updated: May 31, 2026

Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis

Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis

Published on: July 18, 2025

Does model for end-stage liver disease (MELD) require modification?

¹Jaslok Hospital and Research Centre, Dr G Deshmukh Marg, Mumbai 400 026.

The Journal of the Association of Physicians of India

|July 15, 2011

Summary

This summary is machine-generated.

The Model for End-stage Liver Disease (MELD) score predicts survival in liver transplant candidates. MELD-Na is recommended when MELD is inaccurate, and adjustments are suggested for post-transplant survival prediction.

More Related Videos

The Murine Choline-Deficient, Ethionine-Supplemented (CDE) Diet Model of Chronic Liver Injury

The Murine Choline-Deficient, Ethionine-Supplemented (CDE) Diet Model of Chronic Liver Injury

Published on: October 21, 2017

Related Experiment Videos

Last Updated: May 31, 2026

Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis

Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis

Published on: July 18, 2025

The Murine Choline-Deficient, Ethionine-Supplemented (CDE) Diet Model of Chronic Liver Injury

The Murine Choline-Deficient, Ethionine-Supplemented (CDE) Diet Model of Chronic Liver Injury

Published on: October 21, 2017

Area of Science:

Hepatology
Transplantation Medicine
Medical Prognostics

Background:

The Model for End-stage Liver Disease (MELD) score is a standard prognostic tool for cirrhotic patients awaiting liver transplantation.
It assesses serum bilirubin, serum albumin, and the International Normalized Ratio (INR) to predict short-term survival.

Purpose of the Study:

To evaluate the accuracy of the MELD score in predicting survival for liver transplant candidates and recipients.
To identify limitations of the MELD score and propose modifications for improved prognostic accuracy.

Main Methods:

Analysis of MELD score components (serum bilirubin, albumin, INR) in cirrhotic patients.
Comparison of MELD score predictions with actual survival outcomes in pre- and post-liver transplantation cohorts.

Main Results:

The MELD score accurately predicts 3-month survival in approximately 85% of cirrhotic patients awaiting liver transplantation.
MELD-Na is recommended for improved accuracy in a subset of patients where MELD is a poor predictor.
The MELD score demonstrates limited accuracy in predicting survival after liver transplantation.

Conclusions:

The MELD score is a valuable tool for pre-transplant survival prediction but has limitations.
Modifications, such as downgrading the score for recipient age and disease recurrence risk, are recommended to enhance post-transplant survival prediction.